ODQ |
Catalog No.GC10279
One-Click Copy Product Info
|
ODQ es un inhibidor de la guanililciclasa (sGC) de una ,amera competitiva pero irreversible.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 41443-28-1
Sample solution is provided at 25 µL, 10mM.
ODQ es un inhibidor de la guanililciclasa (sGC) de una ,amera competitiva pero irreversible[1-2].
ODQ(10μM) invirtió parcialmente el efecto antiviral de CoPP al inhibir la guanilil ciclasa soluble (sGC) [3]. ODQ(20μM) reduce la capacidad de la naringenina (NAR) para promover la diferenciación osteogénica de las células madre del ligamento periodontal humano (hPDLSCs) [4]. ODQ(30μM) indujo significativamente la apoptosis de las células NCI-H2452 [5].
El tratamiento con ODQ(i.p; 6mg/kg; 8 días) por sí solo puede ralentizar la tasa de crecimiento de los tumores, la combinación de ODQ y Fruquintinib disminuyó aún más el tamaño del tumor[6]. ODQ(25-100μg/mL) puede eliminar el efecto proteger de la decocción de Zhenwu Decoction (ZWD) en la hipertrofia de señalización sGC-cGMP-PKG en pez cebra[7].
References:
[1]. Feelisch M, Kotsonis P, et,al. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation. Mol Pharmacol. 1999 Aug;56(2):243-53. doi: 10.1124/mol.56.2.243. PMID: 10419542.
[2]. Schrammel A, Behrends S, et,al. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol. 1996 Jul;50(1):1-5. PMID: 8700100.
[3]. Wang T, Li S, et,al. Heme oxygenase-1 is an equid alphaherpesvirus 8 replication restriction host protein and suppresses viral replication via the PKCβ/ERK1/ERK2 and NO/cGMP/PKG pathway. Microbiol Spectr. 2024 Apr 2;12(4):e0322023. doi: 10.1128/spectrum.03220-23. Epub 2024 Mar 5. PMID: 38441979; PMCID: PMC10986571.
[4]. Li S, Xiong Z, et,al. Naringenin modulates the NO?cGMP?PKG signaling pathway by binding to AKT to enhance osteogenic differentiation in hPDLSCs. Int J Mol Med. 2024 Aug;54(2):67. doi: 10.3892/ijmm.2024.5391. Epub 2024 Jun 28. PMID: 38940332; PMCID: PMC11232664.
[5]. Ronald Fiscus, et al. ODQ, an inhibitor of soluble guanylyl cyclase (nitric oxide-activated enzyme), enhances the pro-apoptotic effects of cisplatin in human mesothelioma cells. Cancer Res May 1 2007 (67) (9 Supplement) LB-43.
[6]. Zhu J, Yang W, et,al. Pericyte signaling via soluble guanylate cyclase shapes the vascular niche and microenvironment of tumors. EMBO J. 2024 Apr;43(8):1519-1544. doi: 10.1038/s44318-024-00078-5. Epub 2024 Mar 25. PMID: 38528180; PMCID: PMC11021551.
[7].Chen L, Zhou X, et,al. Zhenwu decoction ameliorates cardiac hypertrophy through activating sGC (soluble guanylate cyclase) - cGMP (cyclic guanosine monophosphate) - PKG (protein kinase G) pathway. J Ethnopharmacol. 2023 Jan 10;300:115705. doi: 10.1016/j.jep.2022.115705. Epub 2022 Sep 12. PMID: 36099983.
| Experimentos celulares [1]: | |
Líneas celulares | Células NBL-6 |
Método de preparación | Las células se infectaron con EqHV-8 a un MOI de 0.1 durante 1 h, seguido del tratamiento de células con o sin CoPP (100µM) en presencia o ausencia de ODQ (10µM). |
Condiciones de reacción | 10µM |
Áreas de aplicación | ODQ revirtió parcialmente el efecto antiviral de la protoporfirina de cobalto (CoPP) mediante la generación del virus de progenie EqHV-8. |
| Experimentos con animales [2]: | |
Modelos animales | Ratones C57BL/6J (modelo de tumor LLC) |
Método de preparación | Los ratones recibieron administración oral de 2.5mg/kg de Fruquintinib e inyección intraperitoneal de 6mg/kg de ODQ, ambos a partir del día 6 después de la inyección tumoral, y análisis tumoral en el día 14 después de la inyección tumoral. |
Forma de dosificación | i.p; 6mg/kg; 8 días |
Áreas de aplicación | El tratamiento con ODQ solo redujo el crecimiento tumoral, la combinación de ODQ yd Fruquintinib disminuyó aún más el tamaño del tumor. |
References: | |
| Cas No. | 41443-28-1 | SDF | |
| Chemical Name | 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one | ||
| Canonical SMILES | O=C1ON=C2N1C3=CC=CC=C3N=C2 | ||
| Formula | C9H5N3O2 | M.Wt | 187.16 |
| Solubility | DMF: 30 mg/ml,DMF:PBS (pH 7.2) (1:1): .1 mg/ml,DMSO: 15 mg/ml,Ethanol: .5 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 5.343 mL | 26.7151 mL | 53.4302 mL |
| 5 mM | 1.0686 mL | 5.343 mL | 10.686 mL |
| 10 mM | 534.3 μL | 2.6715 mL | 5.343 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)